Abstract
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 371-374 |
| Number of pages | 4 |
| Journal | British Journal of Cancer |
| Volume | 99 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 22 2008 |
Fingerprint
Keywords
- BRCA1
- BRCA2
- Prostate cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Rapid progression of prostate cancer in men with a BRCA2 mutation. / Narod, S. A.; Neuhausen, S.; Vichodez, G.; Armel, S.; Lynch, H. T.; Ghadirian, P.; Cummings, S.; Olopade, O.; Stoppa-Lyonnet, D.; Couch, Fergus J; Wagner, T.; Warner, E.; Foulkes, W. D.; Saal, H.; Weitzel, J.; Tulman, A.; Poll, A.; Nam, R.; Sun, P.; Danquah, Jessica; Domchek, Susan; Tung, Nadine; Ainsworth, Peter; Horsman, Douglas; Kim-Sing, Charmaine; Maugard, Christine; Eisen, Andrea; Daly, Mary; McKinnon, Wendy; Wood, Marie; Isaacs, Claudine; Gilchrist, Dawna; Karlan, Beth; Nedelcu, Raluca; Meschino, Wendy; Garber, Judy; Pasini, Barbara; Manoukian, Siranoush; Bellati, Christina.
In: British Journal of Cancer, Vol. 99, No. 2, 22.07.2008, p. 371-374.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rapid progression of prostate cancer in men with a BRCA2 mutation
AU - Narod, S. A.
AU - Neuhausen, S.
AU - Vichodez, G.
AU - Armel, S.
AU - Lynch, H. T.
AU - Ghadirian, P.
AU - Cummings, S.
AU - Olopade, O.
AU - Stoppa-Lyonnet, D.
AU - Couch, Fergus J
AU - Wagner, T.
AU - Warner, E.
AU - Foulkes, W. D.
AU - Saal, H.
AU - Weitzel, J.
AU - Tulman, A.
AU - Poll, A.
AU - Nam, R.
AU - Sun, P.
AU - Danquah, Jessica
AU - Domchek, Susan
AU - Tung, Nadine
AU - Ainsworth, Peter
AU - Horsman, Douglas
AU - Kim-Sing, Charmaine
AU - Maugard, Christine
AU - Eisen, Andrea
AU - Daly, Mary
AU - McKinnon, Wendy
AU - Wood, Marie
AU - Isaacs, Claudine
AU - Gilchrist, Dawna
AU - Karlan, Beth
AU - Nedelcu, Raluca
AU - Meschino, Wendy
AU - Garber, Judy
AU - Pasini, Barbara
AU - Manoukian, Siranoush
AU - Bellati, Christina
PY - 2008/7/22
Y1 - 2008/7/22
N2 - Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
AB - Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
KW - BRCA1
KW - BRCA2
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=48249136563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48249136563&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6604453
DO - 10.1038/sj.bjc.6604453
M3 - Article
C2 - 18577985
AN - SCOPUS:48249136563
VL - 99
SP - 371
EP - 374
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -